Dipaite (Pazopanib) 200mg*30 | Acebright China Generic | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

分享
Product description

Generic Information: Dipaite (Pazopanib) 200mg — China-Mainland

Dipaite (地帕特) is a domestically approved Chinese generic of the anti-angiogenic agent pazopanib, produced by Shanghai Acebright Pharmaceuticals Co., Ltd. — a Shanghai-based pharmaceutical manufacturer with a dedicated oncology portfolio. Each pack contains 30 film-coated tablets of 200 mg (0.2 g), the standard strength used in daily pazopanib therapy.

As one of the early domestic pazopanib generics to clear China's drug regulator, Dipaite has widened affordable access to first-line renal cell carcinoma treatment and second-line soft tissue sarcoma care. Its active ingredient and once-daily dosing match the imported originator, while its domestic price point sits far lower than the branded product.

What Is Dipaite Used For?

Clinicians prescribe Dipaite for two advanced malignancies. The first is advanced renal cell carcinoma (RCC), where it is used both as initial treatment and after prior cytokine therapy. The second is advanced soft tissue sarcoma (STS), reserved for patients who have already received chemotherapy. In both settings the goal is to slow tumour growth by cutting off its blood supply.

How Does Dipaite Work?

The active ingredient, pazopanib, belongs to the class of multi-targeted tyrosine kinase inhibitors. It selectively blocks several receptors that drive new blood-vessel formation — vascular endothelial growth factor receptors VEGFR-1, VEGFR-2 and VEGFR-3, plus platelet-derived growth factor receptors PDGFR-α and PDGFR-β, and the c-Kit receptor. Starved of fresh vasculature, the tumour cannot keep growing.

Indications

  • Advanced renal cell carcinoma (RCC) — first-line and post-cytokine therapy.
  • Advanced soft tissue sarcoma (STS) — following prior chemotherapy.

Dosage and Administration

Take 800 mg once a day — that is four 200 mg tablets swallowed whole, without food, at least one hour before or two hours after eating. A single 30-tablet pack lasts roughly a week. Hepatic function and blood pressure need checking because the dose is lowered in liver impairment.

Side Effects

The most frequent complaints are gastrointestinal (diarrhoea, nausea, vomiting, loss of appetite), elevated blood pressure, fatigue and hair colour changes. A boxed warning flags the risk of serious liver injury, so liver tests run before and during treatment. Thyroid suppression, bleeding events and QT-interval prolongation are also possible — report yellowing of the skin, unusual bruising or an irregular heartbeat promptly.

Storage

Keep Dipaite under 30°C, sealed in its original packaging, protected from damp, and well out of children's reach. Do not use past the expiry date shown on the carton.

Why Choose the GLT?

GLT verifies every Dipaite batch against Shanghai Acebright's manufacturing details before shipping, and our China-based sourcing keeps costs close to domestic pricing rather than the originator's US list price. That translates into a materially lower total for long-term therapy, with full purchase documentation and a direct contact line for after-sales questions.

How to Order Dipaite from GLT

Reach GLT on WhatsApp at +86 15234153837 or by email at [email protected] to place an order for Dipaite 200 mg (30 tablets). Share your intended quantity, destination and order type, and we will confirm the batch and lead time before dispatching.

FAQ

Is Dipaite interchangeable with Votrient? Yes — Dipaite is bioequivalent to the originator and delivers the identical active ingredient at the same 200 mg strength; it is manufactured by Shanghai Acebright in China.

How many tablets make up a daily dose? Four 200 mg tablets, taken together once daily on an empty stomach, for a total of 800 mg.

Can GLT ship Dipaite internationally? Yes, we supply Dipaite to buyers worldwide — contact us on WhatsApp or email to check stock.

Related Oncology Products

Tixepa(替尔泊肽)20mg/2mL 和 30mg/2mL 多剂量注射笔 | Drug International | GLT

Tixepa——Drug International Limited (DIL) 替尔泊肽多剂量注射笔,两种官方规格(Tixepa-5=20mg/2mL,Tixepa-7.5=30mg/2mL)用于 2 型糖尿病和肥胖。

Palutini(巴瑞替尼)4mg | 仿制 JAK1/JAK2 抑制剂 | Trans Continental Life Science & Pharmaceuticals (TLPH) | GLT

由 Trans Continental Life Science & Pharmaceuticals (TLPH)(老挝)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

Barinib(巴瑞替尼)2mg | 仿制 JAK1/JAK2 抑制剂 | Drug International Limited | GLT

由 Drug International Limited(孟加拉国)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

Tirzema(替尔泊肽)2.5/5/7.5mg/0.5mL 单剂量注射笔 | Incepta(孟加拉国)| GLT

Tirzema——Incepta Pharmaceuticals 替尔泊肽单剂量注射笔,三种官方规格(2.5/5/7.5mg/0.5mL),用于 2 型糖尿病和体重管理。

Barinat(巴瑞替尼)4mg | 仿制 JAK1/JAK2 抑制剂 | Natco Pharma Limited | GLT

由 Natco Pharma Limited(印度)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。

Olumiant(巴瑞替尼)2mg/4mg 片 | JAK1/JAK2 抑制剂 | 礼来(美国)| GLT

礼来公司的选择性 JAK1/JAK2 抑制剂,用于类风湿关节炎、特应性皮炎和重度斑秃。

奥氟格列隆/奥格列龙(OriYo)0.8–17.2mg 片剂 | 孟加拉仿制药 口服 GLP-1 | GLT

孟加拉国民制药(National Drug Co.)仿制奥氟格列隆,6 剂量递增用于体重管理

Baricent(巴瑞替尼)2mg | 仿制 JAK1/JAK2 抑制剂 | Incepta Pharmaceuticals Ltd. | GLT

由 Incepta Pharmaceuticals Ltd.(孟加拉国)生产的仿制巴瑞替尼(JAK1/JAK2 抑制剂)——用于类风湿关节炎、特应性皮炎和斑秃,是 Olumiant 的平价替代品。